Hypoxia-Inducible Factor-2 Alpha (HIF-2?) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
The Pharma Data
AUGUST 15, 2021
The WELIREG label contains a boxed warning that exposure to WELIREG during pregnancy can cause embryo-fetal harm. The major efficacy endpoint for the treatment of VHL-associated RCC was ORR measured by radiology assessment using RECIST v1.1 About Von Hippel-Lindau Disease. As an inhibitor of HIF-2?, months (range, 2.8
52 
Let's personalize your content